Last mentioned: Mar 10, 2026
STAT Analysis Released
Data confirms a 35% nosedive in Big Pharma antimicrobial R&D over the preceding 60 months.
Small Biotech Crisis
A wave of bankruptcies among small antibiotic developers highlights the 'broken market' for new treatments.
Market Exit Acceleration
Several large pharma entities announce the closure of infectious disease units to focus on chronic therapies.
Baseline Period
Major drugmakers maintain active antimicrobial pipelines before a steady five-year decline begins.
A new analysis reveals a 35% decline in antimicrobial R&D by major pharmaceutical companies over the last five years, highlighting a deepening crisis in the fight against drug-resistant superbugs. The exodus of large-scale investment underscores the persistent lack of economic incentives for developing life-saving antibiotics.
A new analysis reveals a 35% decline in antimicrobial R&D among the world's largest pharmaceutical companies over the last five years. This retreat highlights a deepening crisis in the antibiotic market, where low returns on investment are driving major players toward more lucrative therapeutic areas.